Related Experiment Video
Updated: Apr 1, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
PRMT5-dependent p53 escape in tumorigenesis
1Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.
Abstract:
Extensive studies have characterized mutational disruption of p53 signaling in human cancers. However, the mechanism for bypass of p53 function in tumors retaining wild-type p53 has remained ambiguous. Recent studies suggest that PRMT5, which is frequently elevated in human cancers, cooperates with oncogenic cyclin D1 and leaves marks on p53 by way of arginine methylation, promoting the bypass of wild-type p53, and in doing so, evade apoptosis.
Insights
Protein arginine methyltransferase 5 (PRMT5) promotes cancer cell survival by modifying wild-type p53. This mechanism helps tumors evade apoptosis, even when p53 is functional.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- Mutations in p53 signaling are common in human cancers.
- The mechanisms enabling cancer cells with wild-type p53 to bypass its tumor-suppressive functions are not fully understood.
Purpose of the Study:
- To investigate the role of PRMT5 in the evasion of wild-type p53 tumor suppression.
- To elucidate how PRMT5 contributes to cancer cell survival and apoptosis evasion.
Main Methods:
- Analysis of PRMT5 expression in human cancers.
- Investigating the interaction between PRMT5, cyclin D1, and p53.
- Assessing the effect of PRMT5 on p53 arginine methylation.
- Evaluating the impact of PRMT5-mediated p53 modification on apoptosis.
Main Results:
- PRMT5 is frequently elevated in human cancers.
- PRMT5 cooperates with oncogenic cyclin D1.
- PRMT5 mediates arginine methylation of wild-type p53.
- This modification promotes the bypass of wild-type p53 function, leading to apoptosis evasion.
Conclusions:
- PRMT5 plays a critical role in enabling cancer cells with functional p53 to evade apoptosis.
- Targeting PRMT5 may offer a therapeutic strategy for cancers that retain wild-type p53.
More Related Videos
04:56Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...